Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study
While definitive conclusions on future studies cannot be drawn, the study offers key insights into challenges that should be considered in future research.
Authors
- Melissa L. Santorelli (ORCID: https://orcid.org/0000-0002-2964-7292)
- Oliver Schmalz (ORCID: https://orcid.org/0000-0002-1239-8453)
- Josephine M. Norquist (ORCID: https://orcid.org/0000-0002-1513-8307)
- Thomas W. Burke (ORCID: https://orcid.org/0000-0003-0592-5822)
- Clemens Schulte (ORCID: https://orcid.org/0000-0003-2362-3318)
- David F. Heigener (ORCID: https://orcid.org/0000-0002-7422-1303)
- S Riehl
- Joonas Vainio
- Petra Hoffknecht
- Sabine Bohnet
- Lisa Barthuber
- Markus Knott
- Mathias Hoiczyk
- Alexander Hildner
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Elektrobit (Finland) (FI)
- Universitäres Kinderwunschzentrum Lübeck (DE)
- Marien Hospital Wesel (DE)
- MSD (Germany) (DE)
- Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer (DE)
- Helios Universitätsklinikum Wuppertal (DE)
- Praxis für Hämatologie und Onkologie (DE)
- Klinikum Stuttgart (DE)
- Agaplesion Diakonieklinikum Rotenburg (DE)
- Alcon (China) (CN)
Publication Details
- Journal
- Digital Health
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1177/20552076251348584
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00